<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/569A336F-F052-43FD-BE4A-ED3744F6D8B0"><gtr:id>569A336F-F052-43FD-BE4A-ED3744F6D8B0</gtr:id><gtr:name>Cambimune Limited</gtr:name><gtr:address><gtr:line1>CPC1 CAPITAL PARK , FULBOURN</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB21 5XE</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/569A336F-F052-43FD-BE4A-ED3744F6D8B0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>569A336F-F052-43FD-BE4A-ED3744F6D8B0</gtr:id><gtr:name>Cambimune Limited</gtr:name><gtr:address><gtr:line1>CPC1 CAPITAL PARK , FULBOURN</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB21 5XE</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>99940.0</gtr:offerGrant><gtr:projectCost>166567.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/71F10318-7B29-497E-A681-6F76B2C155CF"><gtr:id>71F10318-7B29-497E-A681-6F76B2C155CF</gtr:id><gtr:firstName>Grant</gtr:firstName><gtr:surname>Austin</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710490"><gtr:id>5E150801-59D1-49B0-BB0A-D4772DAF700E</gtr:id><gtr:title>Applied research of a novel, cost effective virus like particle rabies vaccine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710490</gtr:grantReference><gtr:abstractText>Rabies is an acute, lethal disease caused by a virus infection of the central nervous system.
The rabies virus is most often spread by a bite and saliva from an infected (rabid) animal e.g.,
dogs, bats &amp;amp; raccoons (disease vector). Virtually 100% of those infected with rabies who do
not receive post exposure vaccination will die.
This application is for a Proof of Concept (PoC) grant to test the use our novel virus- like
particle (VLP) vaccine technology platform to produce low cost, highly effective yet safe
rabies vaccines. The application will build on previous research to see if the rabies antigen can
be produced on the surface of immunogenic VLPs at yields orders of magnitude greater than
is possible with currently marketed conventional vaccines. Furthermore, unlike conventional
vaccines produced from live rabies virus grown in cell culture and inactivated, our VLPs,
lacking functional rabies genetic material, will carry no risk of infecting production plant
workers or environmental escape and therefore require lower containment facilities.
The high cost of rabies post-exposure vaccination puts it beyond the reach of large population
segments in the world?s worst affected enzootic regions (China, India &amp;amp; Africa) where
c50,000 lives are lost to the disease each year. Affordable vaccines should allow more
widespread vector and post-exposure vaccination in these markets. This would save thousands
of lives and in so doing also expand and take a significant market share of the rabies vaccine
market. Opportunities also exist in markets such as UK, Europe (mainly travel vaccination)
and North America (vector control, post exposure vaccination and travel vaccination.)
We believe our technology has the potential to cross over to other important global diseases
and open up the opportunity for export to international markets from UK manufacturers.</gtr:abstractText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99940</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710490</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>